Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 ...

Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

AbbVie has agreed a $200 million-plus takeover deal with Roche ... and Tremfya (guselkumab), Eli Lilly's Omvoh (mirikizumab), and Sun Pharma's Ilumya (tildrakizumab). Oral IL-23-directed ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new study has found. This study, conducted by researchers from the University ...

The Billboard 200 is the United States’ main albums chart, compiled by Billboard magazine based on sales and streams in the USA. View the full Billboard 200 here.

as well as the approval of Omvoh for moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY) has seen impressive growth in recent years, largely due to the success of its ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...